FI3936130T3 - Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon - Google Patents

Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon Download PDF

Info

Publication number
FI3936130T3
FI3936130T3 FIEP21178882.3T FI21178882T FI3936130T3 FI 3936130 T3 FI3936130 T3 FI 3936130T3 FI 21178882 T FI21178882 T FI 21178882T FI 3936130 T3 FI3936130 T3 FI 3936130T3
Authority
FI
Finland
Prior art keywords
used according
medicinal composition
composition
hyperkinetic movement
inhibitor
Prior art date
Application number
FIEP21178882.3T
Other languages
English (en)
Finnish (fi)
Inventor
Christopher O'brien
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of FI3936130T3 publication Critical patent/FI3936130T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FIEP21178882.3T 2014-05-06 2015-05-06 Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon FI3936130T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06

Publications (1)

Publication Number Publication Date
FI3936130T3 true FI3936130T3 (fi) 2024-04-23

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21178882.3T FI3936130T3 (fi) 2014-05-06 2015-05-06 Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3936130B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20240011255A (enExample)
CN (3) CN106456629A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3936130T3 (enExample)
ES (2) ES2904526T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20240459T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3936130T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3936130T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3936130T1 (enExample)
SM (2) SMT202200193T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3368534T3 (da) * 2015-10-30 2021-02-15 Neurocrine Biosciences Inc Valbenazin-ditosylat og polymorfer deraf
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
EP3568394A1 (en) 2017-01-10 2019-11-20 Sandoz AG Crystalline valbenazine free base
KR20230170136A (ko) 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP2020512986A (ja) * 2017-04-01 2020-04-30 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN110691596A (zh) * 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3081709A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
KR102447769B1 (ko) 2017-12-26 2022-09-26 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도
US12144899B2 (en) * 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
JOP20200298A1 (ar) 2018-06-14 2020-11-22 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
EA202193012A1 (ru) * 2019-05-09 2022-03-02 Ньюрокрайн Байосайенсиз, Инк. Способы введения определенных ингибиторов vmat2
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) * 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
JP6362601B2 (ja) * 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
US9782398B2 (en) * 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof

Also Published As

Publication number Publication date
EP3139925B1 (en) 2021-12-01
CA2947736A1 (en) 2015-11-12
MX387625B (es) 2025-03-18
RU2016147523A (ru) 2018-06-08
CN112741835A (zh) 2021-05-04
EP4389227A2 (en) 2024-06-26
PL3139925T3 (pl) 2022-03-21
WO2015171802A1 (en) 2015-11-12
SI3936130T1 (sl) 2024-05-31
JP2024153782A (ja) 2024-10-29
EP4389227A3 (en) 2024-09-04
CY1125058T1 (el) 2023-06-09
SMT202400199T1 (it) 2024-07-09
IL248745B (en) 2022-07-01
PT3936130T (pt) 2024-04-17
EP3139925A1 (en) 2017-03-15
KR20240011255A (ko) 2024-01-25
DK3936130T3 (da) 2024-03-25
JP6635945B2 (ja) 2020-01-29
KR20200133003A (ko) 2020-11-25
KR20160147044A (ko) 2016-12-21
CA2947736C (en) 2023-04-18
SI3139925T1 (sl) 2022-04-29
HRP20240459T1 (hr) 2024-06-21
HUE066361T2 (hu) 2024-07-28
US20200101063A1 (en) 2020-04-02
RS62782B1 (sr) 2022-01-31
ES2976207T3 (es) 2024-07-26
RU2016147523A3 (enExample) 2018-12-28
NZ725826A (en) 2023-05-26
RS65359B1 (sr) 2024-04-30
JP2019218407A (ja) 2019-12-26
EP3936130B1 (en) 2024-02-14
HUE057839T2 (hu) 2022-06-28
JP2017514850A (ja) 2017-06-08
AU2015256012B2 (en) 2020-07-23
US20170071932A1 (en) 2017-03-16
IL248745A0 (en) 2017-01-31
US20210196702A1 (en) 2021-07-01
LT3139925T (lt) 2022-01-25
PL3936130T3 (pl) 2024-06-10
KR20250029267A (ko) 2025-03-04
SMT202200193T1 (it) 2022-07-21
PT3139925T (pt) 2022-01-26
CN112741836A (zh) 2021-05-04
EP3936130A1 (en) 2022-01-12
JP2021191799A (ja) 2021-12-16
CN106456629A (zh) 2017-02-22
HRP20220025T1 (hr) 2022-04-01
MX2016014429A (es) 2017-04-06
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
RU2753740C2 (ru) 2021-08-23
DK3139925T3 (da) 2021-12-20
KR20220140647A (ko) 2022-10-18
LT3936130T (lt) 2024-04-25

Similar Documents

Publication Publication Date Title
HRP20240459T1 (hr) Režim za doziranje valbenazina za liječenje hiperkinetskih poremećaja pokreta
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2015522630A5 (enExample)
JP2015038135A5 (enExample)
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
EA201270041A1 (ru) Лечение рассеянного склероза лаквинимодом
JP2017506624A5 (enExample)
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
Kukushkin et al. Results of a randomized double blind parallel study on the efficacy and safety of tolpersione in patients with acute nonspecific low back pain
JP2015519329A5 (enExample)
ME02474B (me) Terapijski režimi
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
FI4212152T3 (fi) Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2017507142A5 (enExample)
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
JP2016505050A5 (enExample)
RU2020123405A (ru) Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе
HRP20190211T1 (hr) Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
HRP20200473T1 (hr) Dimetilaminomikeliolid za uporabu u tretmanu pulmonarne fibroze